Page de couverture de Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies

Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies

Perspectives on Selected Hemophilia Research Presented at ISTH 2025: Nonfactor Replacement Therapies

Auteur(s): Annenberg Center for Health Sciences
Écouter gratuitement

À propos de cet audio

 The treatment of persons with hemophilia continues to evolve, with important advancements that address limitations with factor replacement such as diminished efficacy in patients with inhibitors and the burden of frequent intravenous administration. This 30-minute activity delves into the latest research presented at ISTH 2025, highlighting rebalancing agents and factor VIII mimetics. In addition to discussing details of each trial, Dr. von Drygalski shares her thoughts about its importance and relevance to clinical practice.Annenberg Center for Health Sciences Hygiène et mode de vie sain Troubles et maladies
Épisodes
  • Conclusions

    Conclusions
    Aug 8 2025

    Dr. von Drygalski shares her thoughts about the importance of this research and its relevance to clinical practice.
    Voir plus Voir moins
    1 min
  • Factor VIII Mimetics

    Factor VIII Mimetics
    Aug 1 2025

    Abstract 4: Effectiveness of emicizumab in hemophilia A: A 4th interim analysis of the real-world study EMIIL

    Abstract 5: Prospective evaluation of a defined replacement protocol for peri-operative hemostasis in patients with severe hemophilia A with and without inhibitors on emicizumab prophylaxis undergoing elective major surgeries-final results. (EmiSurg Study)

    Abstract 6: FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab
    Voir plus Voir moins
    14 min
  • A Focus on Rebalancing Agents

    A Focus on Rebalancing Agents
    Aug 1 2025

    Abstract 1: Association of antithrombin levels with efficacy of fitusiran prophylaxis in people with hemophilia A or B with and without inhibitors: a predictive modeling approach

    Abstract 2: Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 study

    Abstract 3: Long-term efficacy of marstacimab in participants with severe hemophilia A or B without inhibitors
    Voir plus Voir moins
    11 min
Pas encore de commentaire